1. Home
  2. DLB vs RGEN Comparison

DLB vs RGEN Comparison

Compare DLB & RGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Dolby Laboratories

DLB

Dolby Laboratories

HOLD

Current Price

$65.99

Market Cap

6.4B

Sector

Miscellaneous

ML Signal

HOLD

Logo Repligen Corporation

RGEN

Repligen Corporation

HOLD

Current Price

$166.36

Market Cap

8.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DLB
RGEN
Founded
1965
1981
Country
United States
United States
Employees
N/A
N/A
Industry
Multi-Sector Companies
Medical/Dental Instruments
Sector
Miscellaneous
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.4B
8.2B
IPO Year
2005
N/A

Fundamental Metrics

Financial Performance
Metric
DLB
RGEN
Price
$65.99
$166.36
Analyst Decision
Strong Buy
Buy
Analyst Count
5
10
Target Price
$93.60
$174.90
AVG Volume (30 Days)
641.3K
682.8K
Earning Date
01-28-2026
10-28-2025
Dividend Yield
2.17%
N/A
EPS Growth
N/A
N/A
EPS
2.62
0.03
Revenue
$1,349,130,000.00
$707,890,000.00
Revenue This Year
$5.03
$17.84
Revenue Next Year
$4.02
$12.44
P/E Ratio
$25.28
$6,507.11
Revenue Growth
5.92
11.74
52 Week Low
$64.02
$102.97
52 Week High
$89.66
$182.52

Technical Indicators

Market Signals
Indicator
DLB
RGEN
Relative Strength Index (RSI) 43.32 59.62
Support Level $65.96 $156.01
Resistance Level $67.60 $167.74
Average True Range (ATR) 1.15 4.65
MACD -0.09 -0.19
Stochastic Oscillator 10.63 92.75

Price Performance

Historical Comparison
DLB
RGEN

About DLB Dolby Laboratories

Dolby Laboratories Inc. develops technologies that enhance audio and video capture, transmission, and playback, enabling high-quality experiences across movies, TV, music, sports, and more. The company designs and manufactures audio, imaging, accessibility, and related hardware and software mainly for cinema, including digital cinema servers and media encryption and packaging tools. It generates the majority of its revenue by licensing its technology, brand, and patents to device manufacturers and by selling cinema hardware and services. It operates as a single reportable segment, with revenue derived mainly from licensing and, to a lesser extent, from premium cinema technologies, across the United States and international markets.

About RGEN Repligen Corporation

Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 58% of 2024 revenue, while chromatography, proteins, and process analytics were 19%, 12%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.

Share on Social Networks: